The primary objective of this study is to define the diagnostic performance and optimal cutoffs of AI-ECG and NT-pro-BNP for the detection of left ventricular dysfunction (LVD, defined as a left ventricular ejection fraction (LVEF) <50%) in cancer patients at 1 year after completion of anthracycline-based chemotherapy.
The purpose of this study is to improve the cardiovascular care of adult cancer survivors. The goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.